Joyce E. Feagin, M.D., with Hematology/Oncology Associates, will be featured on NBC’s Today Show on Thursday, Jan. 12. All this week, the Today Show is celebrating the show’s 60th Anniversary. As part of the anniversary celebration, Today Show producers asked viewers to submit stories about being loyal to Today. Her husband Gerald submitted her story.
The Commission on Cancer (CoC) of the American College of Surgeons has granted its Outstanding Achievement Award to Willis-Knighton Cancer Center as a result of surveys performed during 2010. Willis-Knighton Cancer Center is one of a select group of 90 currently accredited and newly accredited cancer programs across the United States.
The Commission on Cancer (CoC) of the American College of Surgeons has awarded a three-year accreditation with commendation to Willis-Knighton Cancer Center. This accreditation is granted when a program complies with all standards and receives a commendation rating.
Lane R. Rosen, M.D., director of radiation oncology at the Willis-Knighton Cancer Center, was named as the American College of Radiology (ACR) resource to the “H-34 Task Force on Helical IMRT” of the Conference of Radiation Control Program Directors (CRCPD).
Robin A. Lacour, M.D., M.P.H., has joined Destin Black, M.D. at Gynecologic Oncology Associates. The office is located in Suite 420 of the Willis-Knighton Cancer Center, 2600 Kings Highway in Shreveport.
Christopher M. Wilson, M.D., has joined W. Stewart Bundrick, M.D., and Elizabeth Harrel, M.D., at Ark-La-Tex Urology and Prostate Cancer Institute.
Willis-Knighton and the Captains hope to increase awareness to head & neck cancer which is directly attributed to the use of tobacco products including smokeless tobacco. The event also honors the memory of Jason Bland, certified athletic trainer with Willis-Knighton Sports Medicine and Airline High School, who died from head and neck cancer on June 7.
Michael R. Moore, M.D., F.A.C.P., hematologist / oncologist at the Willis-Knighton Cancer Center, has returned from New Orleans where he presented the results of a phase II study at the Poster Session of the American Society of Hematology Meeting. The study was entitled "Efficacy and Safety of Romiplostim in Patients with Low- or Intermediate-Risk Myelodysplastic Syndtome (MDS) Receiving Decitibine."
Willis-Knighton has announced plans to construct Louisiana’s first hospital-based proton beam therapy center adjacent to the Willis-Knighton Cancer Center, setting the stage for cancer patients in the region to have access to this revolutionary technology. This project represents an investment of approximately $30 million in technology, construction and design.